Amedisys Return On Capital Employed from 2010 to 2024

AMED Stock  USD 90.16  0.16  0.18%   
Amedisys' Return On Capital Employed is increasing over the years with slightly volatile fluctuation. Overall, Return On Capital Employed is expected to go to 0.10 this year. During the period from 2010 to 2024 Amedisys Return On Capital Employed annual values regression line had coefficient of variation of  5,926 and r-squared of  0.43. View All Fundamentals
 
Return On Capital Employed  
First Reported
2010-12-31
Previous Quarter
0.09858117
Current Value
0.1
Quarterly Volatility
0.26725089
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Amedisys financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Amedisys' main balance sheet or income statement drivers, such as Depreciation And Amortization of 18.6 M, Interest Expense of 32.8 M or Selling General Administrative of 333.3 M, as well as many indicators such as Price To Sales Ratio of 0.86, Dividend Yield of 3.0E-4 or PTB Ratio of 2.57. Amedisys financial statements analysis is a perfect complement when working with Amedisys Valuation or Volatility modules.
  
Check out the analysis of Amedisys Correlation against competitors.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.

Latest Amedisys' Return On Capital Employed Growth Pattern

Below is the plot of the Return On Capital Employed of Amedisys over the last few years. It is Amedisys' Return On Capital Employed historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Amedisys' overall financial position and show how it may be relating to other accounts over time.
Return On Capital Employed10 Years Trend
Slightly volatile
   Return On Capital Employed   
       Timeline  

Amedisys Return On Capital Employed Regression Statistics

Arithmetic Mean0
Coefficient Of Variation5,926
Mean Deviation0.19
Median0.10
Standard Deviation0.27
Sample Variance0.07
Range1.0534
R-Value0.65
Mean Square Error0.04
R-Squared0.43
Significance0.01
Slope0.04
Total Sum of Squares1.00

Amedisys Return On Capital Employed History

2023 0.0986
2022 0.11
2021 0.17
2020 0.2
2019 0.19
2018 0.31
2017 0.13

About Amedisys Financial Statements

Amedisys stakeholders use historical fundamental indicators, such as Amedisys' Return On Capital Employed, to determine how well the company is positioned to perform in the future. Although Amedisys investors may analyze each financial statement separately, they are all interrelated. For example, changes in Amedisys' assets and liabilities are reflected in the revenues and expenses on Amedisys' income statement, which ultimately affect the company's gains or losses. Understanding these patterns can help in making the right long-term investment decisions in Amedisys. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Return On Capital Employed 0.10  0.10 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
When determining whether Amedisys is a strong investment it is important to analyze Amedisys' competitive position within its industry, examining market share, product or service uniqueness, and competitive advantages. Beyond financials and market position, potential investors should also consider broader economic conditions, industry trends, and any regulatory or geopolitical factors that may impact Amedisys' future performance. For an informed investment choice regarding Amedisys Stock, refer to the following important reports:
Check out the analysis of Amedisys Correlation against competitors.
For information on how to trade Amedisys Stock refer to our How to Trade Amedisys Stock guide.
You can also try the AI Portfolio Architect module to use AI to generate optimal portfolios and find profitable investment opportunities.
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Amedisys. If investors know Amedisys will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Amedisys listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.35)
Earnings Share
2.52
Revenue Per Share
71.004
Quarterly Revenue Growth
0.057
Return On Assets
0.0627
The market value of Amedisys is measured differently than its book value, which is the value of Amedisys that is recorded on the company's balance sheet. Investors also form their own opinion of Amedisys' value that differs from its market value or its book value, called intrinsic value, which is Amedisys' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Amedisys' market value can be influenced by many factors that don't directly affect Amedisys' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Amedisys' value and its price as these two are different measures arrived at by different means. Investors typically determine if Amedisys is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Amedisys' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.